Capsid Aggregation

Capsid aggregation refers to self-association of individual adeno-associated virus (AAV) particles into larger multi-particle species. Aggregates may form during production, purification, concentration, formulation, freeze-thaw, shipping, or storage.

For AAV products, aggregation is an important product-related impurity and stability-related quality attribute because it can affect product consistency, analytical recovery, potency interpretation, particle distribution, and immunogenicity risk. The clinical and CMC relevance of aggregation depends on aggregate level, size distribution, reversibility, assay method, route of administration, dose, formulation, and relationship to biological activity.

Control of aggregation is therefore a key objective of formulation and manufacturing process development.

• On-Column Losses: Large, non-specific aggregates can be filtered out or adsorbed by the SEC column itself, leading to an underestimation of the true aggregate content.
• Quantification Limits: Accurately quantifying very low levels of HMW species can be challenging and requires a highly sensitive and validated method.
• Method-Specific Bias: Different analytical techniques can resolve aggregates differently. For example, light-scattering techniques like DLS are sensitive to very small amounts of large aggregates (intensity-weighted), while SEC provides a more direct area-% that approximates mass-% when detector response per unit mass is similar across species.

• Early Phase (Phase 1–2): The focus is on characterization and process understanding. Sponsors typically assess aggregation propensity using stress studies and suitable analytical methods such as SEC-MALS, AUC, DLS, AF4-MALS, or other product-appropriate techniques. A qualified method may be used to monitor clinical material and support formulation or process decisions.
• Late Phase & Commercial (Phase 3/BLA): As product understanding matures, aggregation monitoring should be aligned with the intended control strategy. If aggregation is included in release or stability specifications, the method should be validated for its intended use, shown to be stability-indicating where applicable, and supported by justified acceptance criteria. Limits for AAV aggregates should be product-specific and based on method capability, manufacturing experience, stability data, and clinical/nonclinical risk assessment rather than transferred directly from monoclonal antibody precedent.

• Patient Risk: Aggregates may increase immunogenicity risk by altering particle presentation, increasing capsid-protein exposure, or changing how the product is processed by the immune system. The relevance of this risk depends on aggregate type, abundance, size distribution, route of administration, dose, and product-specific clinical context.
• Product Risk: Aggregation may reduce the fraction of discrete, well-dispersed AAV particles and can interfere with potency, infectivity/transduction, particle-counting, or recovery assays. The effect on potency should be evaluated with product-specific functional and physicochemical data rather than assumed from aggregate level alone.
• Manufacturing and Stability Risk: Increasing aggregation may indicate formulation instability, purification stress, concentration effects, freeze-thaw sensitivity, shipping stress, or loss of process control. Aggregation trends should be interpreted alongside capsid titer, genome titer, empty/full profile, potency, visible/sub-visible particles, and stability data.

• Purity & Impurities: Aggregates are major form of product-related impurities.
• Potency/Biological Activity: As the percentage of aggregates increases, the percentage of active, discrete particles decreases, leading to a loss of potency.
• Capsid Thermal Stability: A capsid with lower thermal stability is more prone to partial unfolding, which is often a precursor to irreversible aggregation.

Aggregation control is a central consideration in biologics and AAV development, but AAV aggregate limits should be product-specific. Monoclonal antibody experience provides useful context for high-molecular-weight species, but mAb-style limits should not be automatically transferred to AAV products without justification.

In AAV programs, aggregate monitoring commonly relies on a combination of methods because SEC, SEC-MALS, AUC, DLS, AF4-MALS, and microscopy-based techniques can differ in sensitivity, bias, and the aggregate populations they detect. The appropriate control strategy should reflect formulation, process history, route of administration, dose, stability behavior, and clinical/nonclinical risk assessment.

The practical CMC goal is to minimize and trend aggregation, understand when aggregation increases, and justify product-specific acceptance criteria when aggregation is used for release, stability, comparability, or process control.

ICH Q6B: This guidance supports characterization and control of product-related impurities and degradation products where relevant to quality, safety, or efficacy. For AAV products, aggregates can be managed within this broader framework as product-related impurity or degradation-related species.

FDA Immunogenicity Guidance for Therapeutic Protein Products: Although this guidance is focused on therapeutic proteins, it is useful by analogy because aggregation is recognized as a factor that may influence immunogenicity risk. For AAV products, aggregation risk should be interpreted in a product-specific context alongside capsid biology, dose, route of administration, potency, and stability data.